Thank you
This live web event has ended. Thank you for attending.
Description
ACTIVITY OVERVIEW –Mitigating disease progression due to metabolic-associated steatotic liver disease (MASLD) and its related metabolic-associated steatohepatitis (MASH) has been challenging due to a lack of disease-specific therapies. With the approval of the first MASH-specific therapy and several other agents in advanced stages of development comes a new era of disease management. This activity will explore the mechanism of action of thyroid hormone receptor-β (THR-β) agonists and the efficacy of these agents in the treatment of MASH. Recent clinical and safety data of approved and late-stage disease-specific therapies will be examined along with considerations around disease staging to ensure appropriate management. Finally, multiple case-based scenarios will be explored with the goal of tailoring pharmacologic management to each individual patient.
TARGET AUDIENCE – This initiative is intended for hepatology and gastroenterology healthcare providers, as well as other specialty clinicians involved in the management of patients with MASLD/MASH.
FACULTY
Meena B. Bansal, MD FAASLD
Course Director
Professor of Medicine
System Chief, Division of Liver Diseases
Director, MASLD/MASH Center of Excellence
Icahn School of Medicine at Mount Sinai
New York, NY
Quentin Anstee, MBBS, PhD, FRCP
Dean of Research and Innovation
Professor of Experimental Hepatology
Newcastle University
Newcastle upon Tyne, United Kingdom
Elisabetta Bugianesi, MD, PhD
Professor, Division of Gastroenterology
Department of Medical Sciences
University of Torino, Italy
AGENDA
- The Growing Burden of MASLD/MASH: A Call to Action
- THR-β Agonists and Other Disease-Specific Therapies Poised to Change the Paradigm
- Rising to the Need to Improve Diagnosis in the Era of Disease-Specific Therapy
- Clinical Case Challenge: Integrating MASLD/MASH-Specific Therapy Into Practice
- Q&A and Closing Remarks
- Describe the mechanistic and clinical rationale for THR-β agonists as a means of treating MASLD/MASH
- Evaluate the evidence on THR-β agonists and other disease-specific therapy classes, considering various study populations, primary and secondary efficacy endpoints, safety, and tolerability
- Review evolving considerations for non-invasive diagnosis/stratification strategies to facilitate access to MASLD/MASH-specific therapy
- Develop appropriate management paradigms for MASLD/MASH that incorporate pharmacotherapy tailored to individual clinical scenarios
This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC.
This activity is supported by an educational grant from Madrigal Pharmaceuticals.
Criteria for Success
Certificates of completion will be awarded based on the participant’s attendance and submission of the activity evaluation/claim credit form. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.
Credit provided by AKH Inc., Advancing Knowledge in Healthcare
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 1.0AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Type of Activity: Application-based
Fee Information: There is no fee for this educational activity.